Immune Response News and Research

RSS

Study reveals molecular mechanisms of drug resistance in Mycobacterium tuberculosis

A consortium of researchers from Russia, Belarus, Japan, Germany and France led by a Skoltech scientist have uncovered the way in which Mycobacterium tuberculosis survives in iron-deficient conditions by utilizing rubredoxin B, a protein from a rubredoxin family that play an important role in adaptation to changing environmental conditions.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

More new SARS-CoV-2 variants are highly likely

In a recent report posted to the bioRxiv preprint server, researchers from the United Kingdom and Uganda reveal unique protein features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) relative to other representatives of Sarbecoviruses.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Researchers identify mechanism by which dermatomyositis may develop in humans

Dermatomyositis is an idiopathic inflammatory myopathy that has been regarded as an autoimmunity-based disorder, although its pathogenesis remains unclear.

8 Apr 2021

Inhibition of NLRP3 complex can reduce inflammation in melanoma patients

Cancer doctors may soon have a new tool for treating melanoma and other types of cancer, thanks to work being done by researchers at the University of Colorado Cancer Center.

8 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis.

7 Apr 2021

$15.7 million NIMH grant to renew UC Davis Conte Center studying the origins of mental illness

Discovering how infections during pregnancy, such as COVID-19 and influenza, can lead to psychiatric illness and developmental disorders in offspring years later, and how to detect, prevent or treat these disorders, is the subject of a $15.7 million grant from the National Institute of Mental Health to the Conte Center at the University of California, Davis.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

New research could rescue failed immunotherapies for treating solid tumors

New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.

7 Apr 2021

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

The coronavirus disease (COVID-19) first emerged in late December 2019 in Wuhan, China. Though it has been more than one year since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported, it is still unclear how long the antibodies persist in those who have recovered.

7 Apr 2021

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile.

6 Apr 2021

FDA authorizes use of Symbiotica COVID-19 Self-Collected Antibody Test System

The U.S. Food and Drug Administration today announced it has issued an emergency use authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.

6 Apr 2021

Is non-severe SARS-CoV-2 infection characterized by early T cell proliferation?

To date, little evidence has been documented regarding the immune responses after the onset of the symptoms or virus detection. Further, no cross-sectional studies have been conducted that define the time of infection. Thereby, no report is available that explains the relationship between the earliest immune responses to COVID-19 and temporal kinetics. New research deals with this research gap using blood transcriptomics, multiparameter flow cytometry, and T cell receptor (TCR) sequencing methods.

6 Apr 2021

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted to the bioRxiv* server discusses impressively high neutralizing responses elicited with a single dose of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine formulation, which could help turn the tide of the current pandemic if validated.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data

Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. T-cell receptors are found on the surface of immune T cells.

5 Apr 2021

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the SARS-CoV-2.

5 Apr 2021

Immune Response News and Research

Study reveals molecular mechanisms of drug resistance in Mycobacterium tuberculosis

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

More new SARS-CoV-2 variants are highly likely

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Researchers identify mechanism by which dermatomyositis may develop in humans

Inhibition of NLRP3 complex can reduce inflammation in melanoma patients

Bispecific antibodies neutralize SARS-CoV-2 and its variants

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

$15.7 million NIMH grant to renew UC Davis Conte Center studying the origins of mental illness

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

New research could rescue failed immunotherapies for treating solid tumors

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

FDA authorizes use of Symbiotica COVID-19 Self-Collected Antibody Test System

Is non-severe SARS-CoV-2 infection characterized by early T cell proliferation?

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News